Earnings call transcript: Acme United Q1 2026 sees EPS miss amid revenue growth

Acme United reported Q1 2026 EPS of $0.24 versus $0.55 consensus, a 56.4% miss, even as revenue rose 14% year over year to $52.3 million and slightly topped estimates. Net income fell 40% to about $1.0 million, pressured by tariffs, higher SG&A tied to MyMedic, and elevated inventory costs, though management expects tariff impacts to ease over the next three quarters. The stock fell 2.26% pre-market to $44.50.

Analysis

The key read-through is not the headline earnings miss; it’s that ACU is intentionally trading current margin for future throughput, and the market is only partially pricing that. The acquisition mix is boosting top line but also creating a temporary drag from DTC marketing, integration overhead, and working-capital intensity, so the next two quarters should look worse on reported earnings before the operating leverage shows up. That creates a classic “bad quarter, better setup” dynamic if management actually converts the new capacity and brand reach into repeat demand.

The tariff discussion matters more than the quarter itself because it is a timing issue, not a structural one. If management is right that the cost peak is already in inventory and should roll off over the next 2–3 quarters, margin recovery can be abrupt rather than linear, which often catches shorts leaning on trailing EPS. The geopolitical backdrop adds a second-order risk: inventory pre-buying protects revenue continuity but suppresses near-term cash conversion and raises balance-sheet sensitivity if supply chains normalize faster than expected.

The bigger winner may be the portfolio beyond ACU: DTC learnings, automation, and facility consolidation can be replicated across the base business, which means this could be a multi-year gross margin story disguised as a near-term earnings problem. The contradiction is that the stock still screens expensive on current earnings, so the upside case depends on investors underappreciating how much of the spend is front-loaded and how much of the revenue mix is shifting to higher-frequency channels. If promotional activity normalizes in the back half, the next catalyst is not another beat on revenue; it is a sharp improvement in gross margin and SG&A leverage versus depressed first-half comps.

Key Decisions for Investors

• Avoid chasing ACU into the print; wait 4-6 weeks for post-earnings de-rating and look for a re-entry only if the stock trades back to a mid-teens forward P/E on normalized FY27 EPS.
• For a tactical long, buy ACU on weakness only if management confirms tariff roll-off and margin improvement in the next update; target a 2:1 reward/risk into the back-half re-acceleration.
• Pair trade: long ACU vs short a higher-quality consumer/industrial name with no tariff unwind catalyst if you want to express a margin-recovery trade rather than a market beta view; hold 1-2 quarters.
• If options liquidity is workable, consider a modest call spread only after the next quarter, not now; the setup is better for post-miss compression than for immediate upside.
• Monitor working capital and debt metrics closely; if net debt rises again while gross margin fails to recover by Q2/Q3, abandon the long thesis quickly.